The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation
Vasograin Plus represents a major advancement in the treatment of migraine
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
Celecoxib is a nonsteroidal anti-inflammatory drug
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Subscribe To Our Newsletter & Stay Updated